These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30255451)

  • 1. Efficacy and safety of non-transvenous cardioverter defibrillators in infants and young children.
    Müller MJ; Dieks JK; Backhoff D; Schneider HE; Ruschewski W; Tirilomis T; Paul T; Krause U
    J Interv Card Electrophysiol; 2019 Mar; 54(2):151-159. PubMed ID: 30255451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks?
    Krause U; Müller MJ; Wilberg Y; Pietzka M; Backhoff D; Ruschewski W; Paul T
    Europace; 2019 Jan; 21(1):106-113. PubMed ID: 30339209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults? A single-centre study.
    Silvetti MS; Pazzano V; Verticelli L; Battipaglia I; Saputo FA; Albanese S; Lovecchio M; Valsecchi S; Drago F
    Europace; 2018 Dec; 20(12):1966-1973. PubMed ID: 29939256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
    DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Subcutaneous Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death　- Primary Japanese Experience.
    Sasaki S; Tomita H; Tsurugi T; Ishida Y; Shoji Y; Nishizaki K; Kinjo T; Endo T; Nishizaki F; Hanada K; Sasaki K; Horiuchi D; Kimura M; Higuma T; Okamatsu H; Tanaka Y; Koyama J; Okumura K
    Circ J; 2018 May; 82(6):1546-1551. PubMed ID: 29643282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midterm Results of Implantable Cardioverter Defibrillators in Children and Young Adults from a Single Center in Turkey.
    Aykan HH; Karagoz T; Gulgun M; Ertugrul I; Aypar E; Ozer S; Alehan D; Celiker A; Ozkutlu S
    Pacing Clin Electrophysiol; 2016 Nov; 39(11):1225-1239. PubMed ID: 27620455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epicardial and pleural lead ICD systems in children and adolescents maintain functionality over 5 years.
    Tomaske M; Prêtre R; Rahn M; Bauersfeld U
    Europace; 2008 Oct; 10(10):1152-6. PubMed ID: 18701602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right versus left parasternal electrode position in the entirely subcutaneous ICD.
    Bettin M; Dechering D; Frommeyer G; Larbig R; Löher A; Reinke F; Köbe J; Eckardt L
    Clin Res Cardiol; 2018 May; 107(5):389-394. PubMed ID: 29285623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with End-Stage Renal Disease on Dialysis.
    El-Chami MF; Levy M; Kelli HM; Casey M; Hoskins MH; Goyal A; Langberg JJ; Patel A; Delurgio D; Lloyd MS; Leon AR; Merchant FM
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):900-904. PubMed ID: 25952566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.
    Migliore F; Mattesi G; De Franceschi P; Allocca G; Crosato M; Calzolari V; Fantinel M; Ortis B; Facchin D; Daleffe E; Fabris T; Marras E; De Lazzari M; Zanon F; Marcantoni L; Siciliano M; Corrado D; Iliceto S; Bertaglia E; Zecchin M
    J Cardiovasc Electrophysiol; 2019 Jun; 30(6):854-864. PubMed ID: 30827041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications and inappropriate shocks in pediatric patients receiving a subcutaneous implantable cardioverter defibrilator.
    Centeno M; Álvarez García-Rovés R; Pérez-Caballero R; Arenal Á; Atienza F; González-Torrecilla E; Carta A; Ríos-Muñoz GR; Medrano C; Gil-Jaurena JM; Fernández-Avilés F; Ávila P
    Rev Esp Cardiol (Engl Ed); 2024 May; 77(5):362-369. PubMed ID: 38000625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of epicardial implantable cardioverter-defibrillator systems in children: results justify its preference in paediatric patients.
    Winkler F; Dave H; Weber R; Gass M; Balmer C
    Europace; 2018 Sep; 20(9):1484-1490. PubMed ID: 29253120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.